Recent advances of antibody drug conjugates for clinical applications

作     者：Pengxuan Zhao Yuebao Zhang Wenqing Li Christopher Jeanty Guangya Xiang Yizhou Dong Pengxuan Zhao;Yuebao Zhang;Wenqing Li;Christopher Jeanty;Guangya Xiang;Yizhou Dong

作者机构：Division of Pharmaceutics&PharmacologyCollege of Pharmacythe Ohio State UniversityColumbusOH 43210USA School of PharmacyTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Department of Biomedical Engineeringthe Ohio State UniversityColumbusOH 43210USA The Center for Clinical and Translational Sciencethe Ohio State UniversityColumbusOH 43210USA The Comprehensive Cancer Centerthe Ohio State UniversityColumbusOH 43210USA Dorothy M.Davis Heart&Lung Research Institutethe Ohio State UniversityColumbusOH 43210USA Department of Radiation Oncologythe Ohio State UniversityColumbusOH 43210USA Neuroscience ProgramCollege of Medicine&College of Arts and Sciencesthe Ohio State UniversityColumbusOH 43210USA 

出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)

年 卷 期：2020年第10卷第9期

页      面：1589-1600页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the start-up fund from the College of Pharmacy at The Ohio State University 

主　　题：Antibody drug conjugates Antibody Cytotoxic agents Linker Clinical application 

摘      要：Antibody drug conjugates(ADCs)normally compose of a humanized antibody and small molecular drug via a chemical *** decades of preclinical and clinical studies,a series of ADCs have been widely used for treating specific tumor types in the clinic such as brentuximab vedotin(Adcetris?)for relapsed Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma,gemtuzumab ozogamicin(Mylotarg?)for acute myeloid leukemia,ado-trastuzumab emtansine(Kadcyla?)for HER2-positive metastatic breast cancer,inotuzumab ozogamicin(Besponsa?)and most recently polatuzumab vedotin-piiq(Polivy?)for B cell *** than eighty ADCs have been investigated in different clinical stages from approximately six hundred clinical trials to *** review summarizes the key elements of ADCs and highlights recent advances of ADCs,as well as important lessons learned from clinical data,and future directions.